• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Fibrillin-3 (FBN3), Truncated

ACP15941

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15941 Target NameFBN3
Target SynonymsFBN3; KIAA1776Fibrillin-3 [Cleaved into: Fibrillin-3 C-terminal peptide]FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ75N90
Background Information
  • Uniprot Id

    Q75N90

  • Target Species

    Human

  • Target Name

    FBN3

  • Target Full Name

    Fibrillin-3

  • Target Function

    Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-containing microfibrils provide long-term force bearing structural support.

  • Target Subcellular Location

    Secreted, extracellular space, extracellular matrix.

  • Target Protein Families

    Fibrillin family

  • Target Tissue Specificity

    Predominantly expressed in connective tissues such as skeletal muscle, tendon, skin, perichondrium and periosteum. Highly expressed in fetal lung, brain, kidney. Expressed at low level in prostate, testis, mammary gland, uterus, ovary, placenta, bladder,

  • Target Synonyms

    FBN3; KIAA1776Fibrillin-3 [Cleaved into: Fibrillin-3 C-terminal peptide]

Inquire Recombinant Human Fibrillin-3 (FBN3), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification